Nebivolol 1 A Pharma (Nebivolol)

Nebivolol is a selective β1‑adrenergic blocker used in the management of cardiovascular conditions.

• Hypertension: Reduces systolic and diastolic blood pressure, decreasing cardiovascular risk.
• Heart failure with reduced ejection fraction: Improves left‑ventricular function and lowers hospitalization rates.
• Left ventricular systolic dysfunction: Enhances cardiac output in patients with impaired systolic performance.

• Nebivolol binds selectively to β1‑adrenergic receptors, inhibiting catecholamine‑induced stimulation of heart rate and contractility. In addition, it stimulates endothelial nitric‑oxide synthase, leading to nitric‑oxide release and vasodilation, which together lower systemic vascular resistance and blood pressure while supporting cardiac efficiency.

Nebivolol may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: Mild to moderate intensity.
• Dizziness: Often related to blood‑pressure lowering.
• Fatigue: Generalized tiredness, especially at treatment initiation.
• Nasal congestion: Mild obstruction of nasal passages.
• Gastrointestinal discomfort: Nausea or mild abdominal pain.
• Bradycardia: Heart rate below 60 bpm in some patients.

Serious or Rare Side Effects

• Severe bradycardia: Marked slowing of heart rate requiring medical attention.
• Acute heart failure exacerbation: Worsening symptoms of heart failure.
• Allergic reactions: Rash, pruritus, or angioedema.
• Liver enzyme elevation: Significant increase in hepatic transaminases.
• Bronchospasm: Particularly in patients with reactive airway disease.
• QT prolongation: Rare electrical conduction disturbance.

Before initiating Nebivolol, clinicians should assess patient history and comorbidities.

• Cardiovascular assessment: Evaluate for severe bradycardia or advanced heart block.
• Hepatic function: Adjust use in patients with moderate to severe liver impairment.
• Renal function: Monitor in patients with chronic kidney disease.
• Concomitant beta‑blockers: Avoid additive effects that may cause excessive bradycardia.
• Pregnancy and lactation: Use only if potential benefit justifies potential risk.
• Store at below 25°C: Keep in the original packaging, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): May increase nebivolol plasma concentrations.
• Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): Can cause additive bradycardia.
• Other beta‑blockers: Combined use may lead to excessive heart‑rate reduction.

Moderate Interactions (Monitor Closely)

• Antihypertensive agents (e.g., ACE inhibitors, diuretics): May enhance blood‑pressure lowering effect.
• Antidiabetic drugs: Nebivolol may mask hypoglycemia symptoms.
• Antidepressants (e.g., SSRIs): Potential for modest pharmacodynamic interaction.
• NSAIDs: May reduce antihypertensive efficacy.
• Digoxin: Monitor for bradycardia when used together.